NCT01665352View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

TTP054

Administered orally once daily for 12 weeks.

DRUG

Placebo

Administered orally once daily for 12 weeks.

Trial Locations (19)

14609

Site 12, Rochester

23294

Site 15, Richmond

29464

Site 6, Mt. Pleasant

32127

Site 5, Port Orange

33134

Site 4, Coral Gables

40213

Site 7, Louisville

45219

Site 14, Cincinnati

46254

Site 17, Indianapolis

75230

Site 16, Dallas

77072

Site 10, Houston

77074

Site 2, Houston

77450

Site 11, Katy

80220

Site 13, Denver

89101

Site 9, Las Vegas

90057

Site 1, Los Angeles

91911

Site 18, Chula Vista

96814

Site 3, Honolulu

04210

Site 8, Auburn

08611

Site 26, Trenton

Sponsors

Lead Sponsor

vTv Therapeutics
All Listed Sponsors
lead

vTv Therapeutics

INDUSTRY

NCT01665352 - A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter